Oramed Pharmaceuticals Inc.

ORMP | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.70

-$0.04 (-0.84%)

At close: Sep 21, 2026, 4:00 PM ET

$4.71

+$0.01 (+0.21%)

After-hours: Sep 21, 2026, 7:59 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $192.35M

Enterprise Value $176.99M

Beta 1.19

Average Volume 272.38K

Shares Outstanding (Diluted) 42.5M

Shares Change YoY -0.25%

Institutional Ownership 32.47%

Exchange NASDAQ

ISIN US68403P2039

Price Performance

Price Change 1M -2.3%

Price Change 3M 12.7%

Price Change 6M 34.3%

Price Change YTD 61.5%

Price Change 1Y 90.3%

Price Change 3Y 80.8%

Price Change 5Y -79.3%

1M CAGR (ann.) 9.3%

1Y CAGR (ann.) 107.0%

5Y CAGR (ann.) -23.8%

All-Time CAGR -3.2%

Valuation

PE Ratio 1.14

Forward PE N/A

PEG Ratio 0.00

Forward PEG -0.01

PS Ratio N/A

Forward PS 247.10

PB Ratio 0.61

P/FCF Ratio -35.80

P/Adj. FCF Ratio -21.25

P/OCF Ratio -33.57

EV/Sales N/A

EV/EBIT 1.06

EV/EBITDA 1.06

EV/FCF -32.94

Earnings Yield 87.5%

FCF Yield -2.8%

Adj. FCF Yield -4.7%

Financial Health

Net Cash $15.36M

Total Debt $733K

Cash & Short-Term Investments $16.09M

Total Assets $316.24M

Current Ratio 4.98

Quick Ratio 4.98

Debt / Equity Ratio 0.00

Debt / EBITDA 0.00

Debt / FCF -0.14

OCF / Debt -7.60

Interest Coverage 0.00

Altman Z-Score 4.66

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -68.4%

Returns

Return on Assets 47.3%

Return on Equity 73.0%

Return on Invested Capital -3.2%

Return on Capital Employed -4.0%

Return on Tangible Assets 47.3%

Historical Growth (CAGR)

Revenue CAGR 3Y 0.0%

Revenue CAGR 5Y -41.2%

Revenue CAGR 10Y -10.9%

EPS CAGR 3Y 135.0%

EPS CAGR 5Y 198.8%

EPS CAGR 10Y 228.0%

FCF CAGR 3Y -26.7%

FCF CAGR 5Y 37.2%

FCF CAGR 10Y -3.2%

Analyst Forecasts

Analyst Rating Hold

Analyst Count 0

EPS Growth Next 3Y N/A

Revenue Growth Next 3Y N/A

Earnings Date Nov 11, 2026

EPS Estimate (next Q) $0.43

EPS Growth Est (next Q) -62.0%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number $26.75

Graham Upside 469.1%

Lynch Fair Value $102.75

Lynch Upside 2086.2%

Price Target N/A

Price Target Upside N/A

Cash Flow

Operating Cash Flow $-5.57M

Free Cash Flow $-5.37M

Adj. Free Cash Flow $-9.05M

FCF Per Share -$0.13

OCF Per Share -$0.14

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-91K

Operating Income $-14.52M

EBITDA $167.27M

Net Income $174.87M

EPS (Diluted) $4.11

Revenue / Employee N/A

Profit / Employee $13.45M

Employees 13